Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 2/2019

10.05.2019 | Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Literature Review of NIH III Prostatitis

verfasst von: Thomas Farmer, Max Johnston, Alina Milica, Richard Hindley, Amr Emara

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review seeks to review up to date literature surrounding the chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) to provide an overview of the subject. The review includes current understandings of the syndrome, the use of UPOINT, novel treatment strategies and future targets for management.

Recent Findings

Using the US National Institute of Health Chronic Prostatitis Symptom Index helps clinicians to monitor prostatitis symptoms, whilst using UPOINT as guidance of therapies based on patient phenotype(s) has advanced our ability to treat patients suffering with CP/CPPS. Furthermore, novel treatments look beyond traditional prostatic targets to treat CP/CPPS.

Summary

Whilst the use of UPOINT has opened up new targets for the treatment of CP/CPPS, more work is needed to both improve the quality of trials assessing them, as well as further elucidate the underlying pathophysiology behind this troublesome syndrome.
Literatur
1.
2.
Nickel JC, Shoskes DA. Phenotypic approach to the management of the chronic prostatitis/chronic pelvic pain syndrome. BJUI. 2010;106:1252–63.CrossRef
3.
Nickel JC. The three as of chronic prostatitis therapy: antibiotics, α-blockers and anti-inflammatories. What is the evidence? BJUI. 2004;94:1230–3.CrossRef
4.
Thankkinstian A, Attia J, Anothaisintawee T, Nickel JC. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJUI. 2012;110:1014–22.CrossRef
5.
Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J Antimicrob Agents. 2007;31(Suppl1):S85–90.PubMedPubMedCentral
6.
•• Anderson RU, Wise D, Nathanson BH. Chronic prostatitis and/or chronic pelvic pain as a psychoneuromuscular disorder - a meta-analysis. Urology. 2018;120:23–9 Current evidence showing benefit of treating CP/CPPS as psychoneuromuscular disorder. CrossRefPubMed
7.
DeWitt-Foy ME, Nickel JC, Shoskes DA. Management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol Focus. 2019;5(1):2–4.
8.
Shoskes DA, Nickel JC, Dolinga R, Prots D. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology. 2009;73(3):538–42.CrossRefPubMed
9.
Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJUI. 2015;116:509–25.CrossRef
10.
Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. CID. 2010;50:1641–52.CrossRef
11.
Tsivkovskii R, Sabet M, Tarazi Z, Griffith DC, Lomovskaya O, Dudley MN. Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. FEMS Immunol Med Microbiol. 2011;61(2):141–6.CrossRefPubMed
12.
Ogino H, Fujii M, Ono M, Maezawa K, Kizu J, Hori S. In vivo and in vitro effects of fluoroquinolones on lipopolysaccharide-induced pro-inflammatory cytokine production. J Infect Chemother. 2009;15(3):168–73.CrossRefPubMed
13.
Roehrborn CG. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective α-blocker. Urology. 2001;58(6):55–63.CrossRefPubMed
14.
Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE. Intraprostatic urinary reflux: an etiological factor in abacterial prostatitis. Br J Urol. 1982;54:729–31.CrossRefPubMed
15.
Duclos AJ, Lee CT, Shoskes DA. Current treatment options in the management of chronic prostatitis. Ther Clin Risk Manag. 2007;3(4):507–12.PubMedPubMedCentral
16.
Hochreiter WW. Anti-inflammatory therapies for chronic prostatitis. Eur Urol Suppl. 2003;2(2):30–3.CrossRef
17.
Anothaisintawee T, Attia J, Nickel CJ, Thammakraisorn S, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA. 2011;305(1):78–86.CrossRefPubMed
18.
Wagenlehner FM, Schneider H, Ludwig M, Schnitker J, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56(3):544–51.CrossRefPubMed
19.
Nickel JC, Shoskes DA, Wagenlehner FM. Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact. World J Urol. 2013;31(4):747–53.CrossRefPubMed
20.
Bates SM, Hill VA, Anderson JB, Chapple CR, et al. A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2007;99(2):355–9.
21.
Kessler TM, Mordasini L, Weisstanner C, Jüni P, da Costa BR, Wiest R, et al. Sono-electro-magnetic therapy for treating chronic pelvic pain syndrome in men: a randomized, placebo-controlled, double-blind trial. PLoS One. 2014;9(12):e113368.CrossRefPubMedPubMedCentral
22.
Ateya A, Fayez A, Hani R, Zohdy W, Gabbar MA, Shamloul R. Evaluation of prostatic massage in treatment of chronic prostatitis. Urology. 2006;67(4):674–8.CrossRefPubMed
23.
• Magri V, Wagenlehner F, Perletti G, Schneider S. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. J Urol. 2010;184(6):2339–45 Creation of sexual function domain further helps corrolate UPOINT to clinical phenotyping. CrossRefPubMed
24.
Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology. 2010;75(6):1249–53.CrossRefPubMed
25.
Guan X, Zhao C, Ou ZY, Wang L, et al. Use of the UPOINT phenotype system in treating Chinese patients with chronic prostatitis/chronic pelvic pain syndrome: a prospective study. Asian J Androl. 2015;17(1):120–3.CrossRefPubMed
26.
Qin Z, Wu J, Zhou J, Liu Z. Systematic review of acupuncture for chronic prostatitis/chronic pelvic pain syndrome. Medicine (Baltimore). 2016;95(11):e3095.CrossRef
27.
• Liu BP, Wang YT, Chen SD. Effect of acupuncture on clinical symptoms and laboratory indicators for chronic prostatitis/chronic pelvic pain syndrome: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48(12):1977–91 Meta analysis suggesting the benefits of use of acupuncture in CP/CPPS. CrossRefPubMed
28.
Zhang R, Chomistek AK, Dimitrakoff JD, Giovannucci EL, et al. Physical activity and chronic prostatitis/chronic pelvic pain syndrome. Med Sci Sports Exerc. 2015;47(4):757–64.CrossRefPubMedPubMedCentral
29.
Giubilei G, Mondaini N, Minervini A, Saieva C, Lapini A, Serni S, et al. Physical activity of men with chronic prostatitis/chronic pelvic pain syndrome not satisfied with conventional treatments--could it represent a valid option? The physical activity and male pelvic pain trial: a double-blind, randomized study. J Urol. 2007;177(1):159–65.CrossRefPubMed
30.
Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98(4):1154–62.CrossRefPubMed
31.
Nickel JC, Tripp DA, Chuai S, Litwin, et al. Psychosocial variables affect the quality of life of men with chronic prostatitis/chronic pelvic pain syndrome. BJUI. 2007;101:59–64.
32.
Tripp DA, Nickel CJ, Wang Y, Litwin MS, et al. Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis/chronic pelvic pain syndrome. J Pain. 2006;7(10):697–708.CrossRefPubMed
33.
Brünahl CA, Klotz SGR, Dybowski C, Riegel B. Combined cognitive-behavioural and physiotherapeutic therapy for patients with chronic pelvic pain syndrome (COMBI-CPPS): study protocol for a controlled feasibility trial. Trials. 2018;19(1):20.CrossRefPubMedPubMedCentral
34.
Magistro G, Wagenlehner FM, Grabe M, Weidner W, et al. Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol. 2016;69(2):286–97.CrossRefPubMed
35.
Nickel CJ, Shoskes DA, Roehrborn CG, Moyad M. Nutraceuticals in prostate disease: the urologist’s role. Rev Urol. 2008;10(3):192–206.
36.
Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999;54(6):960–3.CrossRefPubMed
37.
Shahed AR, Shoskes DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome: correlation with gram positive bacterial growth and treatment response. J Androl. 2000;21(5):669–75.PubMed
38.
• Morgia G, Russo GI, Urzi D, Privitera S, et al. A phase II, randomized, single-blinded, placebo-controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Arch Ital Urol Androl. 2017;89(2):110–3 RCT showing benefit of using phytotherapies for CP/CPPS. CrossRefPubMed
39.
Jin C, Chen Z, Zhang J. Meta-analysis of the efficacy of Ningmitai capsule on the treatment of chronic prostatitis in China. Medicine(Baltimore). 2018;97(33):e11840.
40.
Zhang K, Zeng X, Chen Y, Zhao R, Wang H, Wu J. Therapeutic effects of Qian-Yu decoction and its three extracts on carrageenan-induced chronic prostatitis/chronic pelvic pain syndrome in rats. BMC Complement Altern Med. 2017;17(1):75.CrossRefPubMedPubMedCentral
41.
Barnes RW, Hadley HL, O’Donoghue EP. Transurethral resection of the prostate for chronic bacterial prostatitis. Prostate. 1982;3(3):215–9.CrossRefPubMed
42.
•• Chopra S, Satkunasivam R, Aron M. Feasibility of robotic radical prostatectomy for medication refractory chronic prostatitis/chronic pelvic pain syndrome: initial results. Indian J Urol. 2016;32(3):238–41 Case report on the use of surgery for CP/CPPS in appropriately selected patients. CrossRefPubMedPubMedCentral
43.
Frazier HA, Spalding TH, Paulson DF. Total prostatoseminal vesiculectomy in the treatment of debilitating perineal pain. J Urol. 1992;148(2):409–11.CrossRefPubMed
44.
Krongrad A, Shenghan L. Laparoscopic prostatectomy for severely symptomatic treatment-refractory chronic prostatitis: preliminary observations from an ongoing phase II clinical trial. UroToday Int J. 2011;4(2):1944–5784.CrossRef
45.
Franco JVA, Turk T, Xiao YT, Iakhno S, et al. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. Cochrane Database Syst Rev. 2018;1:CD01255.
46.
Abdel-Meguid TA, Mosli HA, Farsi H, Alsayyad A, Tayib A, Sait M, et al. Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxin A: a prospective controlled study. Can J Urol. 2018;25(2):9273–80.PubMed
47.
Hong H, Kim CS, Maeng S. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutr Res Pract. 2009;3(4):323–7.CrossRefPubMedPubMedCentral
48.
Tantawy SA, Elgohary HM, Kamel DM. Trans-perineal pumpkin seed oil phonophoresis as an adjunctive treatment for chronic nonbacterial prostatitis. Res Rep Urol. 2018;10:95–101.PubMedPubMedCentral
49.
Hajighorbani M, Ahmadi-Hamedani M, Shahab E, Hayati F, et al. Evaluation of the protective effect of pentoxifylline on carrageenan-induced chronic non-bacterial prostatitis in rats. Inflammopharmacology. 2017;25(3):343–50.CrossRefPubMed
50.
Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008;73(3):233–44.CrossRefPubMed
51.
Tiwari-Woodruff S, Voskuhl RR. Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice. J Neurol Sci. 2009;286(1–2):81–5.CrossRefPubMedPubMedCentral
52.
Acar D, Cayan S, Aktaş S, Tek M. The effect of tamoxifen on bladder functions and histology, and the role of estrogen receptor beta in a rat chemical cystitis model. Neurourol Urodyn. 2007;26(2):309–16.CrossRefPubMed
53.
•• Mizoguchi S, Mori K, Wang Z, Liu T, Funahashi Y, Sato F, et al. Effects of estrogen receptor β stimulation in a rat model of non-bacterial prostatic inflammation. Prostate. 2017;77(7):803–11 New research with promising novel target for management of CP/CPPS. CrossRefPubMedPubMedCentral
Metadaten
Titel
Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Literature Review of NIH III Prostatitis
verfasst von
Thomas Farmer
Max Johnston
Alina Milica
Richard Hindley
Amr Emara
Publikationsdatum
10.05.2019
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 2/2019
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-019-00508-9

Weitere Artikel der Ausgabe 2/2019

Current Bladder Dysfunction Reports 2/2019 Zur Ausgabe

Pediatric Bladder Dysfunction (J Thomas and D Clayton, Section Editors)

The Current Role of Botox in a Pediatric Neurogenic Bladder Condition

Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

Molecular Characteristics of Underactive Bladder

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Urethral Pain Syndrome: A Systematic Review

BPH-Related Voiding Dysfunction (R Lee, Section Editor)

New Diagnostics for Male Lower Urinary Tract Symptoms

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Effects and Complications of Intravesical Instillation of Bacillus Calmette-Guerin Therapy

BPH-Related Voiding Dysfunction (R Lee, Section Editor)

The WATER Study: a Review

Neu im Fachgebiet Urologie

22.04.2024 | Prostatakarzinom | Nachrichten

Stufenschema weist Prostatakarzinom zuverlässig nach

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen